Clinical characteristics and the prognosis of rhabdomyosarcoma - A report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan

European Journal of Pediatric Surgery

Volumn 15, Issue 6, 2005, Pages 409-413

  Suita, S ^a,i   Noguchi, S ^a   Takamatsu, H ^b   Mizote, H ^c   Nagasaki, A ^d   Inomata, Y ^e   Hara, T ^a   Okamura, J ^f   Miyazaki, S ^g   Kawakami, K ^h   Eguchi, H ^c   Tsuneyoshi, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c KURUME UNIVERSITY   (Japan)

^d FUKUOKA CHILDREN S HOSPITAL   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g SAGA UNIVERSITY   (Japan)

^h Kagoshima City Hospital   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

Author keywords

Pediatric oncology; Prognosis; Rhabdomyosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; VINBLASTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HUMAN; INFANT; JAPAN; MAJOR CLINICAL STUDY; MALE; PEDIATRIC SURGERY; PROGNOSIS; RHABDOMYOSARCOMA; SOLID TUMOR; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFANT; INFANT, NEWBORN; JAPAN; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 30344466937     PISSN: 09397248     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872927     Document Type: Article

References (17)

1. Baker KS, Anderson JR, Lobe TE, Wharam MD, Qualman SJ, Raney RB, Ruymann FB, Womer RB, Meyer WH, Link MP, Crist WM. Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: a report from the Intergroup rhabdomyosarcoma study group. J Clin Oncol 2002; 20: 4428-4433
2. Committee on Histological Classification of Childhood Tumors, Japanese Pathological Society. Tumors of Soft Tissues in Histological Classification and Atlas of Tumors in Infancy and Childhood III. Tokyo: Kanabara Company, 1984: 21-23
3. Crist WM, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R et al. The third Intergroup Rhabdomyosarcoma Study-III. J Clin Oncol 1995; 13: 610-630
4. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091-3102
5. Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, Theobald S, Brunat-Mentigny M, Otten J, Voute PA, Habrand JL, Martelli H, Barrett A, Terrier-Lacombe MJ, Oberlin O. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Pediatric Oncology: MMT84. Eur J Cancer 1998; 34: 1050-1062
6. Hara J, Osugi Y, Ohta H, Matsuda Y, Nakanishi K, Takai K, Fujisaki H, Tokimasa S, Fukuzawa M, Okada A, Okada S. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant 1998; 22: 7-12
7. Kaneoko M, Tsuchida Y, Uchino J, Takeda T, Iwafuchi M, Ohnuma N, Mugishima H, Yokoyama J, Nishihira H, Nakada K, Sasaki S, Sawada T, Kawa K, Nagahara N, Suita S, Sawaguchi S. Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for the Treatment of Advanced Neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 190-197
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
9. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, Heyn R, Lawrence W, Newton W, Ortega J et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988; 61: 209-220
10. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71: 1904-1922
11. Nakada K, Committee of Malignant Tumors, Japanese Society of Pediatric Surgeons. The clinical features and prognosis of rhabdomyosarcoma: follow-up studies on pediatric tumors from the Japanese Pediatric Tumor Registry 1971-1980. Part II. Jpn J Surg 1990; 20: 503-509
12. Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, Wiener ES, Maurer HM, Crist WM. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23: 215-220
13. Rodary C, Rey A, Olive D, Flamant F, Quintana E, Brunat-Mentigny M, Often J, Voute PA. Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis. Med Pediatr Oncol 1988; 16: 71-77
14. Sasaki F, Matsunaga T, Iwafuchi M, Hayashi Y, Ohkawa H, Ohira M, Okamatsu T, Sugito T, Tsuchida Y, Toyosaka A, Nagahara N, Nishihira H, Hata Y, Uchino J, Misugi K, Ohnuma N. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 2002; 37: 851-856
15. Suita S, Tajiri T, Sera Y, Takamatsu H, Mizote H, Nagasaki A, Kurosaki N, Hara T, Okamura J, Miyazaki S, Sugimoto T, Kawakami K, Eguchi H, Tsuneyoshi M. Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification. J Pediatr Surg 2000; 35: 1737-1741
16. The Japanese Wilms' Tumor Study Group. Aims of the Japanese Wilms' tumor study (in Japanese). Jpn J Pediatr Surg 2000; 32: 792-797
17. Wexler LH, Helman LJ. Rhabdomyosarcoma. Principles and Practice of Pediatric Oncology. 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1997